Pharmalot

Pharmalot

Lawmakers urge Trump administration to alter trade deal or Americans will pay more for drugs

By Ed Silverman

Pharmalot

Up and down the ladder: The latest comings and goings

By Ed Silverman

Pharmalot

Pharmalittle: Sanders will travel to Canada to buy cheaper insulin; another Alzheimer’s drug fails

By Ed Silverman

Pharmalot

There are fewer opioid prescriptions being written for Medicare Part D beneficiaries

By Ed Silverman

Pharmalot

Germany belatedly finds that most new drugs did not offer meaningful benefits

By Ed Silverman

Pharmalot

Pharmalittle: Trump abandons rebate rule; biotechs fume at Mass. governor’s plan to lower drug prices

By Ed Silverman

Pharmalot

Reckitt will pay $1.4 billion to settle federal probes into marketing of opioid-addiction treatment

By Ed Silverman

Pharmalot

FDA slams Akorn for a laundry list of manufacturing problems that put patients at risk

By Ed Silverman

Pharmalot

Pharma continues to get poor grades when it comes to sharing clinical trial data

By Ed Silverman

Pharmalot

Pharmalittle: White House edges near drug deal with Capitol Hill; U.K. offers plan for antibiotic development

By Ed Silverman

Pharmalot

A Supreme Court ruling may have made it harder to get some info from the FDA

By Ed Silverman

Pharmalot

Do doctors prescribe more Lyrica and similar painkillers because they receive pharma money?

By Ed Silverman

Pharmalot

Pharmalittle: Judge blocks Trump plan to run drug prices in TV ads; former Insys execs cooperate with the feds

By Ed Silverman

Pharmalot

Pharmalittle: Trump plans drug-pricing order; U.S. seeks extradition of Chinese researcher over trade secrets

By Ed Silverman

Pharmalot

Glaxo’s ViiV Healthcare tussles with Kazakhstan over an AIDS drug

By Ed Silverman

Pharmalot

Some insurers are pushing back on the high price for a Novartis gene therapy

By Ed Silverman

Pharmalot

Too many drug makers and universities fail to report trial results in Europe

By Ed Silverman

Pharmalot

Pharmalittle: Trump grows frustrated over drug pricing; FDA enforcement declines under Trump

By Ed Silverman

Pharmalot

HHS gets a new HIV prevention patent, but will the agency demand royalties from Gilead?

By Ed Silverman

Pharmalot

Pharmalittle: Drug prices rose 10.5% this year; Senate committee probes groups tied to opioid makers

By Ed Silverman

Pharmalot

Novo Nordisk’s Jorgensen: If it was easy to correct pricing, we would be doing it already

By Ed Silverman

Pharmalot

Senators widen probe into groups with ties to opioid makers

By Ed Silverman

Pharmalot

Lawmakers seek more info on how FDA inspects plants in China and India

By Ed Silverman

Pharmalot

Pharmalittle: American Pain Society to end operations; first state drug affordability board starts

By Ed Silverman

Pharmalot

Up and down the ladder: The latest comings and goings

By Ed Silverman

Pharmalittle: Data show pharma saturated U.S. with opioids; Swiss extradite Chinese researcher

Pharmalittle: Pharma keeps winning in Washington; J&J faces test as Oklahoma opioid trial wraps up

The FDA disagrees with its own expert panels how often?

Pharmalittle: Glaxo is set to hire a new chairman; Gilead tries to bulk up with new deal

Lawmakers urge Trump administration to alter trade deal or Americans will pay more for drugs

Up and down the ladder: The latest comings and goings

Pharmalittle: Sanders will travel to Canada to buy cheaper insulin; another Alzheimer’s drug fails

There are fewer opioid prescriptions being written for Medicare Part D beneficiaries

Germany belatedly finds that most new drugs did not offer meaningful benefits

Pharmalittle: Trump abandons rebate rule; biotechs fume at Mass. governor’s plan to lower drug prices

Reckitt will pay $1.4 billion to settle federal probes into marketing of opioid-addiction treatment

FDA slams Akorn for a laundry list of manufacturing problems that put patients at risk

Pharma continues to get poor grades when it comes to sharing clinical trial data

Pharmalittle: White House edges near drug deal with Capitol Hill; U.K. offers plan for antibiotic development

A Supreme Court ruling may have made it harder to get some info from the FDA

Do doctors prescribe more Lyrica and similar painkillers because they receive pharma money?

Pharmalittle: Judge blocks Trump plan to run drug prices in TV ads; former Insys execs cooperate with the feds

Pharmalittle: Trump plans drug-pricing order; U.S. seeks extradition of Chinese researcher over trade secrets

Glaxo’s ViiV Healthcare tussles with Kazakhstan over an AIDS drug

Some insurers are pushing back on the high price for a Novartis gene therapy

Too many drug makers and universities fail to report trial results in Europe

Pharmalittle: Trump grows frustrated over drug pricing; FDA enforcement declines under Trump

HHS gets a new HIV prevention patent, but will the agency demand royalties from Gilead?

Pharmalittle: Drug prices rose 10.5% this year; Senate committee probes groups tied to opioid makers

Novo Nordisk’s Jorgensen: If it was easy to correct pricing, we would be doing it already

Senators widen probe into groups with ties to opioid makers

Lawmakers seek more info on how FDA inspects plants in China and India

Pharmalittle: American Pain Society to end operations; first state drug affordability board starts

Up and down the ladder: The latest comings and goings

Pharmalot

Sign up for our Daily Recap newsletter